Search

Displaying results 6291 - 6300 of 10000 in total
  1. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].

  2. Drug

    Amedalin

    go.drugbank.com/drugs/DB09188
    Experimental

    Amedalin is a selective norepinephrine reuptake inhibitor developed in the 1970s. … It has no significant effect on reuptake of serotonin and dopamine and no antihistamine or anticholinergic properties. This drug was never marketed.

  3. Drug

    Canosimibe

    go.drugbank.com/drugs/DB19723
    Investigational

    Canosimibe is under investigation in clinical trial NCT00729027 (Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia).

  4. Drug

    Cagrilintide

    go.drugbank.com/drugs/DB18887
    Investigational

    With Metformin With or Without an SGLT2 Inhibitor). … Cagrilintide is under investigation in clinical trial NCT06221969 (A Research Study to See How Much Cagrisema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated

    Synonyms: L-Prolinamide, N-(19-carboxy-1-oxononadecyl)-L-γ-glutamyl-L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-α-glutamyl-L-phenylalanyl-L-leucyl-L-arginyl-L-histidyl
  5. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis). … Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics

  6. Drug

    Taragarestrant

    go.drugbank.com/drugs/DB21574
    Investigational

    Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).

  7. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    Furvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.

  8. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria

  9. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

    Synonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  10. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represent...